Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL23327843 | 1.00 | STING1 (0.67) | STING1 | |
| SCHEMBL19436532 | 0.99 | STING1 (0.68) | STING1 | |
| SCHEMBL22150070 | 0.95 | STING1 (0.75) | STING1 | |
| SCHEMBL22312656 | 0.92 | STING1 (0.62) | STING1 | |
| SCHEMBL22135066 | 0.88 | STING1 (0.57) | STING1 | |
| SCHEMBL22121165 | 0.88 | STING1 (0.59) | STING1 | |
| SCHEMBL28522082 | 0.87 | STING1 (0.56) | STING1 | |
| SCHEMBL19451818 | 0.87 | STING1 (0.59) | STING1 | |
| SCHEMBL20075498 | 0.86 | STING1 (0.56) | STING1 | |
| SCHEMBL24465500 | 0.86 | STING1 (0.59) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| EP-4032885-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885 |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885 |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | STING1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.